ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRAY
Previous Symbol
CUSIPN/A
Phone440-703-3210
Debt
Debt-to-Equity Ratio0.25
Current Ratio6.47
Quick Ratio5.56
Price-To-Earnings
Trailing P/E Ratio-6.05
Forward P/E Ratio-7.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$34.04 million
Price / Sales17.69
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.03 per share
Price / Book209.67
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-72,170,000.00
Net Margins-105.09%
Return on Equity-105.63%
Return on Assets-38.20%
Miscellaneous
Employees139
Outstanding Shares95,730,000
Market Cap$602.14 million
OptionableOptionable
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.39) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.17. The business had revenue of $17.70 million for the quarter, compared to analysts' expectations of $17.77 million. Viewray had a negative net margin of 105.09% and a negative return on equity of 105.63%. The business's revenue was up 45.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.19) earnings per share. View Viewray's Earnings History.
When is Viewray's next earnings date?
What guidance has Viewray issued on next quarter's earnings?
Viewray issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-80 million, compared to the consensus revenue estimate of $86.65 million.
What price target have analysts set for VRAY?
8 analysts have issued 12-month price targets for Viewray's stock. Their forecasts range from $7.00 to $20.00. On average, they expect Viewray's stock price to reach $13.3125 in the next twelve months. This suggests a possible upside of 111.6% from the stock's current price. View Analyst Price Targets for Viewray.
What is the consensus analysts' recommendation for Viewray?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Northland Securities analysts commented, "We now expect Elekta to begin a full commercial launch beginning Q1-19 (calendar)." (12/6/2018)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $13 on VRAY. VRAY has succeeded in bringing an MRI linear accelerator (linac) to market when its larger competitors could not. Its differentiated technology has the potential to change radiation therapy long term, but VRAY’s commercial launch is only in its infancy. Positive early clinical data are driving physician interest, but the price of the system has a significant premium (~50%) to existing linacs. VRAY, like many small capital equipment companies, has a good amount of risk, but we think momentum is building." (12/6/2018)
- 3. BTIG Research analysts commented, "PT to $14 from $10 VRAY preannounced 2Q rev and reported gross orders of $34.6M Friday coming in in line with consensus. Shares were probably pressured by GMs of ~0% due to one-time issues and expected cash use for the year being increased $10M. We continue to expect VRAY to require additional funding by 1H19. We like the new mgmt team’s track record both as operators and sellers of companies and expect an improvement in commercial execution. That said we felt the stock had overrun a bit to near $13 and would have moved to Neutral but with shares pulling back now still see them compelling. We are raising our out year PT to $14. While we still see VRAY as compelling we have learned quite a bit about potential new competition in MagnetTx (Private), whom we recently visited in Edmonton." (8/7/2018)
- 4. Mizuho analysts commented, "We were at the Advanced Applications of MR-Guided Radiotherapy Symposium in Amsterdam on March 16th, 2018. The event was very well attended with approximately 200 people; most were potential customers who showed strong interest in ViewRay’s MRIdian. We highlight our key takeaways from the conference and additional insights into the MRI Linac below. Overall, we maintain our view that ViewRay has leadership in real time imaging guided LINAC today." (4/19/2018)
Has Viewray been receiving favorable news coverage?
News coverage about VRAY stock has been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Viewray earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Are investors shorting Viewray?
Viewray saw a increase in short interest in November. As of November 15th, there was short interest totalling 20,201,891 shares, an increase of 10.6% from the October 31st total of 18,267,345 shares. Based on an average daily volume of 2,184,752 shares, the short-interest ratio is currently 9.2 days. Currently, 30.3% of the shares of the stock are short sold. View Viewray's Current Options Chain.
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include NxStage Medical (NXTM), CONMED (CNMD), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Fonar (FONR), Electrocore (ECOR), Zynex (ZYXI), Stereotaxis (STXS), Second Sight Medical Products (EYES), Edap Tms (EDAP) and IRIDEX (IRIX).
When did Viewray IPO?
(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Who are Viewray's major shareholders?
Viewray's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fosun International Ltd (21.90%), FMR LLC (12.37%), BlackRock Inc. (5.98%), Perceptive Advisors LLC (4.92%), Vanguard Group Inc. (3.15%) and Vanguard Group Inc (3.15%). Company insiders that own Viewray stock include Ajay Bansal, Fmr Llc, Henry A Mckinnell, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.
Which major investors are selling Viewray stock?
VRAY stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Acuta Capital Partners LLC, Asymmetry Capital Management L.P., Essex Investment Management Co. LLC, Prudential Financial Inc., Falcon Point Capital LLC, Thompson Siegel & Walmsley LLC and Lido Advisors LLC. Company insiders that have sold Viewray company stock in the last year include Fmr Llc, James F Dempsey and Orbimed Advisors Llc. View Insider Buying and Selling for Viewray.
Which major investors are buying Viewray stock?
VRAY stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Fosun International Ltd, HealthCor Management L.P., FMR LLC, BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc. and Partner Fund Management L.P.. Company insiders that have bought Viewray stock in the last two years include Ajay Bansal, Henry A Mckinnell, International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $6.29.
How big of a company is Viewray?
Viewray has a market capitalization of $602.14 million and generates $34.04 million in revenue each year. The company earns $-72,170,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Viewray employs 139 workers across the globe.
What is Viewray's official website?
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (NASDAQ VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
